Monthly Archives: November 2017

http://www.lslog.com/viking-hits-primary-endpoint-in-phase-2-hip-fracture-trial/Viking hits primary endpoint in phase 2 hip fracture trial

Viking hits primary endpoint in phase 2 hip fracture trial

Viking hits primary endpoint in phase 2 hip fracture trial A phase 2 trial of Viking Therapeutics’ VK5211 has hit its primary endpoint. The nonsteroidal selective androgen receptor modulator boosted […]

http://www.lslog.com/pharmas-contentious-inter-partes-reviews-come-under-supreme-court-scrutiny/Pharma's contentious inter partes reviews come under Supreme Court scrutiny

Pharma's contentious inter partes reviews come under Supreme Court scrutiny

Pharma’s contentious inter partes reviews come under Supreme Court scrutiny As several blockbuster drugs have faced patent challenges in recent years, many top drugmakers have pulled no punches in their […]

http://www.lslog.com/new-teva-ceo-shakes-up-structure-and-executive-ranks-as-major-layoffs-loom/New Teva CEO shakes up structure and executive ranks as major layoffs loom

New Teva CEO shakes up structure and executive ranks as major layoffs loom

New Teva CEO shakes up structure and executive ranks as major layoffs loom New Teva CEO Kare Schultz is getting down to business—and quickly. Monday, the troubled Israeli drugmaker unveiled […]

http://www.lslog.com/learning-how-flies-spread-bacteria-could-spark-new-methods-to-track-outbreaks/Learning how flies spread bacteria could spark new methods to track outbreaks

Learning how flies spread bacteria could spark new methods to track outbreaks

Learning how flies spread bacteria could spark new methods to track outbreaks When scientists in Singapore sequenced the genes of 116 houseflies, they discovered that flies pick up bacteria on […]

http://www.lslog.com/biogen-inks-alkermes-deal-to-defend-multiple-sclerosis-turf/Biogen inks Alkermes deal to defend multiple sclerosis turf

Biogen inks Alkermes deal to defend multiple sclerosis turf

Biogen inks Alkermes deal to defend multiple sclerosis turf Biogen has struck a deal to protect its blockbuster multiple sclerosis franchise Tecfidera from the threat of Alkermes’ ALKS 8700. The […]

http://www.lslog.com/jj-lilly-and-az-diabetes-medications-get-another-helping-of-real-world-heart-benefits/J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits

J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits

J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits Last year, real-world data showed that SGLT2 diabetes medications could significantly cut heart failure hospitalizations and all-cause […]

http://www.lslog.com/allergan-sued-for-scheming-to-protect-restasis-and-its-not-just-about-the-tribal-license/Allergan sued for scheming to protect Restasis—and it’s not just about the tribal license

Allergan sued for scheming to protect Restasis—and it’s not just about the tribal license

Allergan sued for scheming to protect Restasis—and it’s not just about the tribal license Allergan has taken intense heat lately for trying to protect its big-selling Restasis from rivals by […]

http://www.lslog.com/takeda-spins-off-cancer-assets-to-incubated-startup/Takeda spins off cancer assets to incubated startup  

Takeda spins off cancer assets to incubated startup  

Takeda spins off cancer assets to incubated startup   A team of ex-Takeda scientists has struck out on its own with cancer assets licensed from the drugmaker. The resulting biotech, […]

http://www.lslog.com/fda-lifts-second-trial-hold-for-prescients-lead-drug-with-one-to-go/FDA lifts second trial hold for Prescient’s lead drug, with one to go

FDA lifts second trial hold for Prescient’s lead drug, with one to go

FDA lifts second trial hold for Prescient’s lead drug, with one to go Slowly but surely, Australia’s Prescient Therapeutics is getting its lead cancer program back on track, with two […]

http://www.lslog.com/glaxosmithkline-turns-up-the-heat-on-gilead-with-landmark-2-drug-hiv-win/GlaxoSmithKline turns up the heat on Gilead with landmark 2-drug HIV win

GlaxoSmithKline turns up the heat on Gilead with landmark 2-drug HIV win

GlaxoSmithKline turns up the heat on Gilead with landmark 2-drug HIV win GlaxoSmithKline’s two-drug HIV bet just paid off. Tuesday, the FDA approved Juluca, the first complete treatment regimen for […]